Comparison of United Kingdom (UK) and United States (U.S.) hypertension treatment status, physical activity and prospective mortality risk

Chenna Wang[1,2], Raaj K. Biswas[1,3], Nicholas A. Koemel[1,4], Matthew N. Ahmadi[1,4]

[1]Mackenzie Wearables Research Hub, Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia

[2]Concord Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia

[3]School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia

[4]Turner Institute for Brain and Mental Health, Monash University, Victoria, Australia

Corresponding author:

Chenna Wang

Address for correspondence:

Concord Medical Education Centre, Concord Repatriation General Hospital, Concord West, New South Wales, Australia.

Email address:

cwan3359@uni.sydney.edu.au

Clinical trial number: not applicable

ABSTRACT

Background: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline lowered diagnostic threshold for hypertension, encouraging earlier treatment initiation in the U.S. compared to UK, where the National Institute for Health and Care Excellence (NICE) guideline recommends higher thresholds. No comparative study evaluating how different hypertension guidelines and physical activity are jointly associated with mortality outcomes in two countries.

Aims: This study compared hypertension prevalence, treatment uptake, blood pressure (BP) levels, and mortality between the UK Biobank (UKBB) and the U.S. National Health and Nutrition Examination Survey (NHANES). We evaluated whether moderate-to-vigorous physical activity (MVPA) modifies mortality risk among different hypertension subgroups (normotensive, medicated hypertension, and unmedicated hypertension).

Methods: We harmonized demographic, biomarker, lifestyle, and accelerometer data from UKBB (n=63,452) and NHANES (n=7,397). Comprehensive weighting methods were applied in both cohorts. Accelerometry data was classified using a validated two-stage machine learning Random Forest algorithm. Associations between MVPA and all-cause mortality were examined with restricted cubic spline regression and visualized using Kaplan-Meier survival curves.

Results: NHANES showed a higher proportion of treated hypertension (29.9%) and lower average blood pressure (SBP/DBP: 122.2/70.7 mmHg) compared to UKBB (11.7% treated; SBP/DBP: 136.0/81.3 mmHg). Despite lower BP levels, cardiovascular mortality was higher in UKBB (10.3 per 10,000 person-years) compared to NHANES (4.0 per 10,000 person-years). In both cohorts, greater MVPA was linked to lower mortality risk, with the strongest association observed among medicated hypertensives. Notably, NHANES participants with treated hypertension and low MVPA (<10.7 minutes/day) experienced a steeper survival decline, falling to 74% by year 8, compared to 91% in normotensives and 79% in untreated hypertensives.

Conclusion: Despite higher treatment prevalence and lower average BP levels in NHANES,

mortality remained higher compared with UKBB, suggesting that differences in mortality patterns

may relate to broader cardiometabolic profiles and PA patterns beyond pharmacological

management alone. Across both cohorts, higher levels of MVPA were associated with lower all-

cause mortality, with the strongest associations were observed among individuals with medicated

hypertension.

Introduction

Hypertension is a leading modifiable risk factors for premature cardiovascular mortality and long-term disability worldwide, affecting an estimated 1.39 billion adults worldwide [1-3]. Elevated BP is consistently associated with increased mortality risk from ischemic heart disease and stroke [2, 4]. Effective BP control is therefore essential to alleviate the global cardiovascular disease (CVD) burden.

However, definitions of hypertension differ across national guidelines, influencing both prevalence estimates and treatment strategies. The 2017 ACC/AHA guideline lowered the diagnostic threshold for hypertension to BP ≥130/80 mm Hg, advocating earlier initiation of pharmacologic treatment [5]. By contrast, the UK's NICE guideline maintains a higher threshold of BP ≥140/90 mm Hg, resulting in more conservative management practices [6]. These divergent thresholds raise critical questions regarding their respective impacts on hypertension detection, treatment uptake, and long-term cardiovascular outcomes. Evidence from the ESPRIT trial, shows that while intensive systolic blood pressure (SBP) lowering (<120 mm Hg) does not reduce total stroke incidence over 3.4 years, it can halve the risk of haemorrhagic stroke after about one year of treatment [7], underscoring how the benefits of tighter control depend on stroke subtype, patient characteristics, and the duration of exposure.

Physical activity (PA) has been widely recognized as a key nonpharmacological component in hypertension management. Regular PA lowers BP through improvements in vascular function and autonomic regulation, effects that tend to be more pronounced in people with hypertension [8-11]. Combining regular PA with pharmacologic treatment produces synergistic benefits, substantially lowering cardiovascular risk [9]. Despite these known relationships, a cross-national accelerometer study suggests that Americans, particularly those over age 50, are markedly less active than UK adults [12]. These findings suggest important cross-national differences in PA patterns. Despite clear evidence supporting early intervention and regular PA for hypertension management, it remains

unclear to what extent differences in national hypertension guidelines and PA patterns contribute to

cardiovascular outcomes.

Compounding these differences, evidence indicates that cardiovascular mortality rates in the U.S. are

substantially higher than those observed in other high-income countries, such as the UK [13, 14]. Taken

together, these findings indicate that lower treatment thresholds in the U.S. have not necessarily

corresponded with better cardiovascular outcomes. This pattern may reflect broader differences in

cardiometabolic risk profiles and PA patterns.

This study uses data from two large, population-based cohorts, UKBB and NHANES, to compare

hypertension prevalence, treatment patterns, and mortality under unified hypertension criteria. The

study aims to explore whether accelerometer-measured PA levels modify the association between

hypertension status and mortality within each cohort.

Methods

Study Design and Data Sources

Our study utilizing existing data from two well-established population-based cohorts: UKBB and

NHANES [15-18]. These datasets include detailed demographic, behavioural, and clinical information,

making them well-suited to evaluate how national hypertension guidelines and PA patterns influence

mortality.

UKBB is a large, population-based cohort study established to investigate factors contributing to

major diseases in middle-aged and older adults. It recruited 500,000 adults aged 40 to 69 years

during 2006–2010 [16, 19]. UKBB data are linked to longitudinal mortality records through NHS Digital

for participants in England and Wales, and through the NHS Central Register for participants in

Scotland [20]. Wearables-based PA data were collected from a subset of 103,617 participants, each

wearing triaxial accelerometers (Axivity AX3) on the wrist continuously for seven days at a

sampling frequency of 100Hz [16, 21].

NHANES is a recurring national survey conducted by the U.S. Centres for Disease Control and

Prevention (CDC) to assess the health and nutritional status of the non-institutionalized civilian

population. In addition to cross-sectional data, NHANES is linked to longitudinal mortality follow-

up through the National Death Index (NDI) [22]. The linked mortality files provide detailed individual-

level time-to-event data, including date and cause of death, duration of follow-up, and mortality

status. During the 2011-2014 cycles, a subsample of participants wore triaxial accelerometers

(ActiGraph GT3X+) on wrist for seven consecutive days, recording data at 80 Hz sampling

frequency [17, 23].

Eligibility Criteria and Data Extraction

We included participants aged 20 years or older if they have valid BP measurements, complete

accelerometer data, and no missing values for key exposure and outcome variables. We conducted

data harmonisation to align variable definitions and ensure consistency between UKBB and

NHANES. We standardized variables using consistent definitions, measurement units, and clinically

relevant cut-offs across cohorts. PA data derived from accelerometry was classified using a two-

stage machine learning Random Forest algorithm, validated in prior studies [24-30]. In the first stage,

10-second windows were assigned to one of four activity classes (sedentary, standing utilitarian

movements, walking activities, or running/high energetic activities). They were then mapped to

sedentary, light (<100 mg), moderate ($\geq$100 mg), or vigorous ($\geq$400 mg) intensity levels [28-31]. The

total duration of activity in each intensity band was aggregated across all valid wear days.

Before conducting mortality analyses, we applied further exclusions to improve the validity of risk

estimates. Participants with incomplete mortality data were removed. We excluded participants who

rated their health as poor or fair to minimise confounding by baseline frailty [28-30]. We excluded

individuals who died within the first year of follow-up to reduce reverse causality risk [28-30].

Statistical Analysis Plan

Participants were categorised into three mutually exclusive hypertension groups based on the 2017

ACC/AHA guideline: (1) normotensive (SBP <130 mm Hg and DBP <80 mm Hg without BP-

lowering medications), (2) unmedicated hypertension (SBP ≥130 mm Hg or DBP ≥80 mm Hg

without BP-lowering medications), and (3) medicated hypertension (self-reported use of

antihypertensive medications) [5]. This classification was applied uniformly across both datasets,

facilitating direct comparisons between cohorts. We selected the 2017 ACC/AHA guideline because

it marked a paradigm shift in hypertension management in the U.S., while most other countries

maintain the long-standing benchmark of 140/90 mmHg [5, 32]. Despite different diagnostic thresholds,

there is strong international agreement that individuals at high atherosclerotic cardiovascular disease

(ASCVD) risk should aim for a BP target of <130/80 mmHg [33].

To mitigate the influence of extreme outliers, we winsorized moderate-to-vigorous physical activity

(MVPA) and measurements of SBP and DBP at the 2.5th and 97.5th percentiles [24, 26, 28-30]. We applied

robust weighting methods on both cohorts [34-36]. For UKBB, we applied inverse probability weighting

(IPW) based on recent work by van Alten et al. to correct for selection bias due to non-random

volunteer participation [37]. For NHANES, we incorporated sampling weights provided by the

National Centre for Health statistics (NCHS) to produce unbiased, population-level estimates

representative of the non-institutionalized U.S. civilian population [17].

We used Cox proportional hazards regression models to examine the relationship between MVPA

tertiles and all-cause mortality, separately within each hypertension group in both cohorts [28-30, 38].

Covariates included age, sex, ethnicity, smoking status, alcohol intake, fruit and vegetable

consumption, educational attainment, previous CVD, family history of CVD, sleep duration, and

light physical activity (LPA) energy expenditure. We used forest plots to present the hazard ratios

(HRs) and 95% confidence intervals (CIs) for the intermediate and high MVPA tertiles relative to the

low MVPA reference group. Additionally, we generated covariate-adjusted Kaplan-Meier survival

curves to estimate survival probabilities across hypertension subgroups stratified by MVPA tertiles

within each cohort.

All statistical analyses were conducted using R (version 4.4.1).

Subgroup and sensitivity analysis

To further validate the robustness of the primary findings, we conducted several subgroup and

sensitivity analyses. First, given the differing age distributions between cohorts, we restricted the

NHANES sample to adults aged 40–69 years to match the UKBB age range (Supplementary Figure

5–6). Second, we excluded participants with self-reported cardiovascular disease at baseline to

minimise reverse causation (Supplementary Figure 7–8) [28-30, 38]. To address the markedly higher

baseline MVPA levels observed in UKBB compared with NHANES, we applied NHANES-derived

MVPA tertile thresholds uniformly to both datasets (Supplementary Figure 9). This allowed direct

comparison of survival outcomes at comparable MVPA levels. In addition, we conducted a

sensitivity analysis using unweighted data from UKBB and NHANES to o evaluate whether the

application of weighting methods in the primary analyses materially altered the observed survival

patterns (Supplementary Figure 10).

Results

Participants demographics and characteristics

The weighted baseline demographic, behavioural, and clinical characteristics of participants from

UKBB and NHANES are presented in Supplementary Table 1, while the unweighted characteristics

are shown in Supplementary Table 2. The UKBB sample included 63,452 participants with a mean

age of 58.2 years (SD = 8.3) and the NHANES sample consisted of 7,397 individuals, who were

younger (mean age = 49.3 years, SD = 16.6). The ethnic composition also varied markedly: over

94% of UKBB participants identified as White, whereas NHANES included approximately 68%

White, 11% Black, 4% Asian, and 16% Other (Supplementary Table 1; Supplementary Figure 1).

Lifestyle differences between cohorts were also evident. For example, PA patterns further

highlighted disparities: non-exercisers were more common in NHANES (46.4%) than in UKBB

(32.2%), and daily duration of MVPA was approximately double in UKBB (40.0 ± 25.2 min/day)

compared to NHANES (21.0 ± 17.4 min/day). Average daily alcohol intake was moderately higher

in NHANES (2.6 ± 2.2 units/day) compared to UKBB (1.9 ± 2.3 units/day). NHANES participants

had higher average waist circumference and body mass index (BMI) (100.2 cm and 29.3 kg/m²,

respectively) relative to their UKBB counterparts (88.3 cm and 26.7 kg/m²). Despite these indicators

of higher cardiometabolic risk in NHANES, SBP and DBP readings were paradoxically lower than

in UKBB. However, this apparent advantage in BP did not translate into survival benefit.

Cardiovascular mortality was more than three times higher in NHANES (2.3%) than in UKBB

(0.7%; Supplementary Table 1, Figure 1).

Across both cohorts, participants with medicated hypertension showed more adverse cardiometabolic

profiles than their unmedicated hypertensive counterparts. These individuals were older (UKBB:

63.9 vs. 58.6 years; NHANES: 60.8 vs. 50.5 years) and more metabolically compromised in terms of

HbA1C, HDL cholesterol, and triglycerides profiles. PA levels were also lower in this group. In

UKBB, mean MVPA was 33.4 minutes per day compared to 40.1 minutes among unmedicated

hypertensives. In NHANES, the gap was larger (13.8 vs. 22.9 minutes per day). Cardiovascular

mortality was highest among medicated hypertensives in both datasets (UKBB: 1.7%, NHANES:

5.1%, Figure 1). These trends suggest that lower PA levels may compound the residual risk despite

pharmacological treatment in medicated hypertension group.

BP Profiles and Treatment Prevalence

The distribution of hypertension status under the 2017 ACC/AHA guideline differed substantially

between cohorts. In UKBB, 29.7% of participants were normotensive, 58.6% had unmedicated

hypertension, and 11.7% were receiving antihypertensive treatment. NHANES presented a different

pattern: 50.7% were normotensive, 19.4% had unmedicated hypertension, and 29.9% were treated

(Supplementary Figure 2). These differences suggest that U.S. adults were more likely to be

diagnosed and treated with antihypertensives, prompted by the lower treatment threshold.

All-cause mortality analysis

Cox analysis

In multivariable-adjusted models, higher levels of MVPA were associated with lower all-cause

mortality risk in participants with medicated hypertension in UKBB when compared with the low

MVPA tertile. In NHANES, only the intermediate MVPA tertile was significantly associated with

lower mortality risk in medicated hypertension group (Supplementary Figure 4). Compared with the

low MVPA tertile, the high MVPA tertile was associated with a HR of 0.60 (95% CI 0.41–0.88) in

UKBB and 0.48 (95% CI 0.21–1.11) in NHANES, while the intermediate MVPA tertile was

associated with an HR of 0.69 (95% CI 0.49–0.98) in UKBB and 0.47 (95% CI 0.24–0.94) in

NHANES. In the unmedicated hypertension and normotensive subgroup, no statistically significant

associations were observed. Across most hypertension categories, point estimates generally indicated

lower mortality risk with higher MVPA, except in NHANES normotensives. Within NHANES,

medicated hypertension had relatively narrower CIs than the other two hypertension groups because

its total number of events (n = 260) was more than three times higher than in unmedicated

hypertension (n = 78) or normotensives (n = 78). In the NHANES medicated hypertension group, the

high MVPA tertile had a hazard ratio of 0.48 with a wider 95% CI of 0.21 to 1.11, likely due to

having fewer deaths events (n = 26), less than half the number in the intermediate tertile (n = 53).

Kaplan–Meier survival curves

Covariate-adjusted Kaplan–Meier survival curves were used to depict the cumulative incidence of

all-cause mortality over time across three hypertension groups, stratified by MVPA tertiles, in

UKBB and NHANES (Figure 2). In UKBB, survival probabilities remained above 90% throughout

the follow-up period across all MVPA strata, with minimal divergence between hypertension groups.

However, medicated hypertensive participants in the low MVPA tertile showed an earlier and

slightly steeper decline in survival probability compared to their normotensive and unmedicated

hypertensive counterparts, while higher MVPA tertiles showed convergence of survival curves

across hypertension groups.

In contrast, NHANES displayed clear separation of survival curves among hypertension groups,

most evident in participants in low MVPA tertile. Medicated hypertensives in this group showed a

steep decline in survival probability beginning early in the follow up period, reaching approximately

74% by year 8. This was substantially lower than normotensive and unmedicated hypertensive

groups, which retained higher probabilities closer to 91% and 79%, respectively. However, these

disparities were less evident in the intermediate and high MVPA strata, where survival curves for all

groups converged above 90% at year 8. These patterns suggest that higher MVPA are associated

with a lower mortality risk among individuals receiving antihypertensive treatment in both cohorts.

Sensitivity analysis

Sensitivity analyses supported the robustness of the main findings. Aligning NHANES to the UKBB

age range and excluding participants with baseline cardiovascular disease did not materially alter the

associations between MVPA, hypertension status, and survival. Applying NHANES-derived MVPA

tertiles to both datasets provided clearer separation of survival curves at lower activity levels,

supporting the interpretation that increased MVPA mitigates mortality risks across hypertension

strata. In addition, analyses using unweighted data yielded Kaplan–Meier survival curves that were

largely consistent with those from the weighted primary analyses.

Discussion

Key findings

The observed differences in hypertension status between UKBB and NHANES are closely linked to

distinct diagnostic and treatment criteria set by NICE and ACC/AHA guidelines. Specifically, the

ACC/AHA 2017 guideline defines hypertension at a lower threshold. It defines stage 1 hypertension

as SBP 130–139 mmHg or DBP 80–89 mmHg and recommends medication for adults within this

range if their estimated 10-year ASCVD risk is 10% or higher [5]. By contrast, treatment under NICE

typically starts at clinic BP ≥160/100 mmHg or ≥140/90 mmHg when significant cardiovascular risk

factors or target organ damage exist [6].

Despite lower mean BP among medicated hypertensive participants in NHANES (130.8/71.0

mmHg) compared with UKBB (147.2/85.8 mmHg), cardiovascular mortality remained higher in

NHANES (5.1% vs 1.7%). One potential explanation for the difference in cardiovascular mortality

rates involves differences in overall cardiometabolic health profiles. NHANES participants exhibited

poorer glycaemic control (5.7% vs. 5.4% in UKBB), lower HDL (52.9 mg/dL vs. 56.4 mg/dL), and

greater obesity burden as indicated by waist circumference (100.2 cm vs. 88.3 cm) and BMI (29.3

kg/m² vs. 26.7 kg/m²). Additionally, NHANES participants showed less favourable lifestyle

behaviours overall, particularly less daily MVPA (21.0 vs. 40.0 minutes/day). MVPA is a key

lifestyle factor due to its robust and well-established relationship with cardiovascular and all-cause

mortality [39-41]. MVPA can be objectively measured, allowing for precise evaluation of its health

impact. Therefore, this study focused on examining MVPA's role in mitigating mortality risk in

hypertension subgroups.

Higher MVPA levels were associated with lower all-cause mortality risk, especially among

medicated hypertensive participants in both cohorts. Compared with the low MVPA tertile, the

intermediate tertile was associated with a HR of 0.69 (95% CI: 0.49–0.98) in UKBB and 0.47 (95%

CI: 0.24–0.94) in NHANES. Covariate-adjusted Kaplan-Meier survival curves supported this, with

NHANES medicated hypertensive individuals in the lowest MVPA tertile (0.3–10.7 minutes/day)

experiencing significantly lower survival probabilities (~74% at year 8), compared to over 90%

survival in the intermediate (10.8–24.8 minutes/day) and high (≥24.8 minutes/day) MVPA tertiles.

These findings indicate that the association between MVPA and mortality varies by treatment status,

with the effect most evident among medicated hypertensive individuals. Regular PA modulates the

renin-angiotensin-aldosterone system, thereby improving BP control [10, 11]. PA also reduces

sympathetic tone, lowers peripheral vascular resistance, and enhances vascular function [42]. Together,

these mechanisms may help contextualize the observed associations between MVPA and lower

mortality among medicated hypertensive participants.

We observed no statistically significant association between MVPA and all-cause mortality among

normotensive participants. This observation aligns with prior findings that individuals who are

already healthy may experience smaller measurable benefits from increased PA compared with those

at higher risk [43]. To better understand this result, we examined the distribution of mortality causes in

this subgroup. Among all recorded deaths, only 15.9% were attributable to cardiovascular causes,

while 59.5% were attributed to cancer. This suggests that in normotensive individuals, cancer-related

mortality may predominate and dilute the overall association between MVPA and all-cause

mortality.

Clinical implication

Our findings emphasize the insufficiency of antihypertensive medication alone in mitigating

mortality risk, particularly when other cardiometabolic risk factors or unhealthy lifestyle behaviours

persist. Recognizing this complexity, clinicians should adopt a comprehensive, multifactorial

approach that concurrently targets BP regulation, glycaemic and lipid optimisation, and sustained

lifestyle modifications.

Among modifiable risk factors, intensive lifestyle interventions can significantly lower

cardiovascular risk [44, 45]. Among the lifestyle factors, our study highlights the pronounced mortality

benefit of increased MVPA among medicated hypertensive patients. Regular PA not only lowers BP

[46, 47], but also is associated with lower risk of excessive weight gain, cardiovascular disease, and all-

cause mortality across diverse populations, including adults with preexisting chronic condition [48, 49].

Even modest increases in activity can produce significant health benefits among the least active

individuals [48]. Our findings reinforce this by showing that among medicated hypertensives in

NHANES, increasing MVPA from low to intermediate tertile was associated with an increase in 8-

year survival from approximately 74% to over 90%. Clinicians should routinely prescribe PA

alongside medications, supported by structured counselling and multidisciplinary teams [50].

U.S. adults exhibit a higher burden of cardiometabolic risk factors alongside wider socioeconomic

inequalities than their British counterparts [51, 52]. These disparities are partly driven by systemic

differences in healthcare structure and funding [53-55]. These system-level distinctions highlight that

optimal hypertension management requires not only clinical and behavioural interventions but also

policies that address affordability of primary care and social infrastructure. Among these public

health policies, this study draws particular attention to the social determinants that shape PA.

Individual efforts must be supported by community infrastructure and accessible facilities.

Neighbourhoods with connected street networks, accessible public transport, and plentiful parks led

to significantly higher PA levels across diverse cities [56]. Therefore, integrated, system-level

interventions connecting clinical recommendations to supportive community environments can more

effectively sustain behavioural changes and ultimately improve population health.

Strength and limitation

Our study's strengths include the use of wearable devices to objectively measure PA. Extensive

evidence shows that self-reported measures provide only crude estimates of activity levels due to

recall and reporting biases, whereas wearables provide more objective estimates on intensity and

duration [57, 58]. Furthermore, we used aligned analytic strategies across two large, independent

population-based cohorts, facilitating direct comparison between UKBB and NHANES. The

availability of rich demographic, lifestyle, and clinical data in both cohorts enabled comprehensive

covariate adjustment, supporting more robust mortality analysis.

Our study also had several limitations. The one-week accelerometer measurement period might not

adequately capture long-term patterns, especially given that PA behaviours fluctuate across the life

course [59]. Second, in UKBB, biomarker and accelerometry data were obtained approximately five

years apart (baseline assessment in 2006–2010 and accelerometer measurements in 2013–2015). This

temporal gap introduces potential inconsistencies, as participants' hypertension profiles, medication

use, or PA patterns could have changed during this period. Third, we lacked information on

participants' adherence to prescribed medications, which may have influenced the observed

associations, especially when comparing medicated and unmedicated hypertension groups. Fourth,

BP readings were taken once and cannot confirm chronic hypertension status, distinguish between

controlled and uncontrolled hypertension within the medicated group, or assess individual

trajectories of BP over time. In addition, we noted wider CIs in NHANES compared with UKBB,

particularly in the unmedicated hypertension and normotensive subgroups. This pattern likely

reflects substantially fewer all-cause mortality events in NHANES compared with UKBB

(Supplementary Table 3), which diminished statistical power and amplified uncertainty in HR

estimates. Future studies should aim to obtain long-term accelerometry data, access general practice

records to assess medication adherence and repeated BP measurements, and include data from

broader settings, particularly from low- and middle-income countries and datasets with greater

volumes of mortality events.

Conclusion

In conclusion, our cross-cohort comparative analysis highlights that higher levels of MVPA were

consistently associated with lower all-cause mortality risks, with the most pronounced associations

observed among individuals already receiving antihypertensive treatment. Despite higher rates of

antihypertensive medication use and lower average BP readings in NHANES, cardiovascular

mortality remained higher compared to UKBB. These findings suggest that variation in mortality

patterns may reflect broader cardiometabolic profiles and PA patterns beyond pharmacological

hypertension treatment alone. The results provide context for public health initiatives and clinical

guidelines to consider how PA counselling and pharmacological management may jointly relate to

long-term mortality outcomes across different population settings.

List of abbreviations: ACC/AHA (American College of Cardiology/American Heart Association),

ASCVD (atherosclerotic cardiovascular disease), BMI (body mass index), BP (blood pressure), CDC

(Centers for Disease Control and Prevention), CI (confidence interval), CMD (cardiometabolic

diseases), CVD (cardiovascular disease), DBP (diastolic blood pressure), HbA1c (hemoglobin A1c),

HDL (high-density lipoprotein cholesterol), HR (hazard ratio), IPW (inverse probability weighting),

LPA (light physical activity), MVPA (moderate-to-vigorous physical activity), NCHS (National

Center for Health Statistics), NDI (National Death Index), NHANES (National Health and Nutrition

Examination Survey), NHS (National Health Service), NICE (National Institute for Health and Care

Excellence), PA (physical activity), RF (random forest), SBP (systolic blood pressure), SD (standard

deviation), UK (United Kingdom), UKBB (UK Biobank), U.S. (United States).

Declaration

Ethic approval and consent to participate: In UKBB, ethical approval for data collection was

obtained from the North West Multi-Centre Research Ethics Committee. The NHANES protocol was

approved by the US NHANES institutional review board and National Center for Health Statistics

Research ethics review board. All participants provided written informed consent.

Consent for publication: Not applicable.

Availability of data and materials: NHANES data are available

at www.cdc.gov/nchs/nhis/index.htm, and data from UK Biobank are available on application

at www.ukbiobank.ac.uk/register-apply.

Competing interests: We declare no competing interests.

Author's contributions: CW, RKB, NAK, and MNA were major contributors to the study design,

data analysis, drafting of the manuscript, and manuscript revision. All authors read and approved the

final manuscript.

References
351
1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and

injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic

analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2224-2260. 2012/12/19.

DOI: 10.1016/s0140-6736(12)61766-8.

2. Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood

Pressure of at Least 110 to 115 mm Hg, 1990-2015. *Jama* 2017; 317: 165-182. 2017/01/18. DOI:

10.1001/jama.2016.19043.

3. Mills KT, Stefanescu A and He J. The global epidemiology of hypertension. *Nat Rev Nephrol*

2020; 16: 223-237. 2020/02/07. DOI: 10.1038/s41581-019-0244-2.

4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to

vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Lancet 2002; 360: 1903-1913. 2002/12/21. DOI: 10.1016/s0140-6736(02)11911-8.

5. Whelton PK, Carey RM, Aronow WS, et al. 2017

ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,

detection, evaluation, and management of high blood pressure in adults: a report of the American

College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Journal of the American College of Cardiology 2018; 71: e127-e248.

6. National Institute for Health and Care Excellence: Guidelines. *Hypertension in adults:*

diagnosis and management. London: National Institute for Health and Care Excellence (NICE)

Copyright © NICE 2023., 2023.

7. Li J, Lei L, Li Y, et al. Effect of Intensive Blood Pressure Control on Stroke: A Prespecified

Secondary Analysis of the ESPRIT Trial. *JACC* 2025.

8. Lesniak KT and Dubbert PM. Exercise and hypertension. *Curr Opin Cardiol* 2001; 16: 356-

359. 2001/11/13. DOI: 10.1097/00001573-200111000-00007.

9.   Hou X, Yue S, Xu Z, et al. Joint Modifiable Risk Factor Control and Incident Stroke in

Hypertensive Patients. *J Clin Hypertens (Greenwich)* 2024; 26: 1274-1283. 2024/09/28 22:42. DOI:

10.1111/jch.14905.

10.   Maris SA, Meyer KM, Murray G, et al. Physical Activity and the Acute Hemodynamic

Response to ACE Inhibition in Hypertension. *American Journal of Lifestyle Medicine* 2022; 16: 538-

545. DOI: 10.1177/1559827620935367.

11.   Goessler K, Polito M and Cornelissen VA. Effect of exercise training on the renin-

angiotensin-aldosterone system in healthy individuals: a systematic review and meta-analysis.

Hypertens Res 2016; 39: 119-126. 2015/09/25. DOI: 10.1038/hr.2015.100.

12.   Kapteyn A, Banks J, Hamer M, et al. What they say and what they do: comparing physical

activity across the USA, England and the Netherlands. *J Epidemiol Community Health* 2018; 72:

471-476. 2018/04/13. DOI: 10.1136/jech-2017-209703.

13.   Acosta E, Mehta N, Myrskylä M, et al. Cardiovascular Mortality Gap Between the United

States and Other High Life Expectancy Countries in 2000-2016. *J Gerontol B Psychol Sci Soc Sci*

2022; 77: S148-s157. 2022/02/24. DOI: 10.1093/geronb/gbac032.

14.   Pritchard C, Porter S, Rosenorn-Lanng E, et al. Mortality in the USA, the UK and Other

Western Countries, 1989–2015: What Is Wrong With the US? *International Journal of Health

Services* 2021; 51: 59-66. DOI: 10.1177/0020731420965130.

15.   Allen N, Sudlow C, Downey P, et al. UK Biobank: Current status and what it means for

epidemiology. *Health Policy and Technology* 2012; 1: 123-126.

16.   Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying

the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015; 12:

e1001779. 20150331. DOI: 10.1371/journal.pmed.1001779.

17.   Statistics NCfH. NHANES Survey Methods and Analytic Guidelines. 2024.

18.   Terry AL, Chiappa MM, McAllister J, et al. Plan and Operations of the National Health and

Nutrition Examination Survey, August 2021-August 2023. *Vital and Health statistics Ser 1,*

Programs and Collection Procedures 2024: 1-21.

19.   Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related

Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol*

2017; 186: 1026-1034. DOI: 10.1093/aje/kwx246.

20.   Biobank U. Mortality data: linkage to death registries. 2023.

21.   Doherty A, Jackson D, Hammerla N, et al. Large scale population assessment of physical

activity using wrist worn accelerometers: the UK biobank study. *PloS one* 2017; 12: e0169649.

22.   Prevention CfDCa. NCHS Data Linked to NDI Mortality Files,

https://www.cdc.gov/nchs/data-linkage/mortality.htm (2024, accessed June 25th 2025).

23.   Koffman L and Muschelli J. Minute level step counts and physical activity data from the

National Health and Nutrition Examination Survey (NHANES) 2011-2014.

24.   Stamatakis E, Ahmadi MN, Gill JMR, et al. Association of wearable device-measured

vigorous intermittent lifestyle physical activity with mortality. *Nat Med* 2022; 28: 2521-2529.

20221208. DOI: 10.1038/s41591-022-02100-x.

25.   Pavey TG, Gilson ND, Gomersall SR, et al. Field evaluation of a random forest activity

classifier for wrist-worn accelerometer data. *J Sci Med Sport* 2017; 20: 75-80. 20160623. DOI:

10.1016/j.jsams.2016.06.003.

26.   Ahmadi MN, Clare PJ, Katzmarzyk PT, et al. Vigorous physical activity, incident heart

disease, and cancer: how little is enough? *Eur Heart J* 2022; 43: 4801-4814. DOI:

10.1093/eurheartj/ehac572.

27.   Stamatakis E, Ahmadi MN, Friedenreich CM, et al. Vigorous Intermittent Lifestyle Physical

Activity and Cancer Incidence Among Nonexercising Adults: The UK Biobank Accelerometry

Study. *JAMA Oncol* 2023; 9: 1255-1259. DOI: 10.1001/jamaoncol.2023.1830.

28.   Koemel NA, Ahmadi MN, Biswas RK, et al. Vigorous intermittent lifestyle physical activity

(VILPA) and mortality risk among US adults: a wearables-based national cohort study. *Int J Behav*

Nutr Phys Act 2026; 23 20260130. DOI: 10.1186/s12966-026-01876-2.

29.   Stamatakis E, Koemel NA, Biswas RK, et al. Minimum and optimal combined variations in

sleep, physical activity, and nutrition in relation to all-cause mortality risk. *BMC Med* 2025; 23: 111.

20250226. DOI: 10.1186/s12916-024-03833-x.

30.   Koemel NA, Ahmadi MN, Biswas RK, et al. Can incidental physical activity offset the

deleterious associations of sedentary behaviour with major adverse cardiovascular events? *Eur J*

Prev Cardiol 2025; 32: 77-85. DOI: 10.1093/eurjpc/zwae316.

31.   Hildebrand M, VT VANH, Hansen BH, et al. Age group comparability of raw accelerometer

output from wrist- and hip-worn monitors. *Med Sci Sports Exerc* 2014; 46: 1816-1824. DOI:

10.1249/MSS.0000000000000289.

32.   Vidal-Petiot E. Thresholds for Hypertension Definition, Treatment Initiation, and Treatment

Targets: Recent Guidelines at a Glance. *Circulation* 2022; 146: 805-807. DOI:

doi:10.1161/CIRCULATIONAHA.121.055177.

33.   Vemu PL, Yang E and Ebinger JE. Moving Toward a Consensus: Comparison of the 2023

ESH and 2017 ACC/AHA Hypertension Guidelines. *JACC Adv* 2024; 3: 101230. 2024/09/17. DOI:

10.1016/j.jacadv.2024.101230.

34.   Stamatakis E, Owen KB, Shepherd L, et al. Is Cohort Representativeness Passe?

Poststratified Associations of Lifestyle Risk Factors with Mortality in the UK Biobank.

Epidemiology 2021; 32: 179-188. 2021/01/26. DOI: 10.1097/EDE.0000000000001316.

35.   Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between

accelerometry measured physical activity and sedentary time and all cause mortality: systematic

review and harmonised meta-analysis. *BMJ* 2019; 366: l4570. 20190821. DOI: 10.1136/bmj.l4570.

36. Carlson SA, Fulton JE, Pratt M, et al. Inadequate physical activity and health care

expenditures in the United States. *Prog Cardiovasc Dis* 2015; 57: 315-323. 20140809. DOI:

10.1016/j.pcad.2014.08.002.

37. van Alten S, Domingue BW, Faul J, et al. Reweighting UK Biobank corrects for pervasive

selection bias due to volunteering. *Int J Epidemiol* 2024; 53 2024/05/08. DOI: 10.1093/ije/dyae054.

38. Koemel NA, Biswas RK, Ahmadi MN, et al. Minimum combined sleep, physical activity,

and nutrition variations associated with lifeSPAN and healthSPAN improvements: a population

cohort study. *eClinicalMedicine* 2026; 92. DOI: 10.1016/j.eclinm.2025.103741.

39. Kraus WE, Powell KE, Haskell WL, et al. Physical Activity, All-Cause and Cardiovascular

Mortality, and Cardiovascular Disease. *Med Sci Sports Exerc* 2019; 51: 1270-1281. 2019/05/17.

DOI: 10.1249/mss.0000000000001939.

40. Bakker EA, Lee D-c, Hopman MT, et al. Dose–response association between moderate to

vigorous physical activity and incident morbidity and mortality for individuals with a different

cardiovascular health status: A cohort study among 142,493 adults from the Netherlands. *PLoS*

medicine 2021; 18: e1003845.

41. Lopez JPR, Gebel K, Chia D, et al. Associations of vigorous physical activity with all-cause,

cardiovascular and cancer mortality among 64 913 adults. *BMJ Open Sport & Exercise Medicine*

2019; 5.

42. Pescatello LS, Franklin BA, Fagard R, et al. American College of Sports Medicine position

stand. Exercise and hypertension. *Med Sci Sports Exerc* 2004; 36: 533-553. 2004/04/13. DOI:

10.1249/01.mss.0000115224.88514.3a.

43. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between

accelerometry measured physical activity and sedentary time and all cause mortality: systematic

review and harmonised meta-analysis. *bmj* 2019; 366.

44.   Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary

Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American

Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019; 140: e596-e646.

DOI: doi:10.1161/CIR.0000000000000678.

45.   Ornish D, Scherwitz LW, Billings JH, et al. Intensive Lifestyle Changes for Reversal of

Coronary Heart Disease. *JAMA* 1998; 280: 2001-2007. DOI: 10.1001/jama.280.23.2001.

46.   Pescatello LS, Franklin BA, Fagard R, et al. Exercise and Hypertension. *Medicine & Science*

in Sports & Exercise 2004; 36: 533-553. DOI: 10.1249/01.Mss.0000115224.88514.3a.

47.   Cornelissen VA and Smart NA. Exercise training for blood pressure: a systematic review and

meta-analysis. *J Am Heart Assoc* 2013; 2: e004473. 2013/03/26. DOI: 10.1161/jaha.112.004473.

48.   Health UDo and Services H. 2018 Physical activity guidelines advisory committee scientific

report. 2018: Part F. Chapter 6. .

49.   Powell KE, King AC, Buchner DM, et al. The Scientific Foundation for the Physical Activity

Guidelines for Americans, 2nd Edition. *Journal of Physical Activity and Health* 2019; 16: 1-11. DOI:

10.1123/jpah.2018-0618.

50.   Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to Promote Physical Activity

and Dietary Lifestyle Changes for Cardiovascular Risk Factor Reduction in Adults. *Circulation*

2010; 122: 406-441. DOI: doi:10.1161/CIR.0b013e3181e8edf1.

51.   Bridger Staatz C, Gutin I, Tilstra A, et al. Midlife health in Britain and the United States: a

comparison of two nationally representative cohorts. *International Journal of Epidemiology* 2024;

53. DOI: 10.1093/ije/dyae127.

52.   Banks J, Marmot M, Oldfield Z, et al. Disease and Disadvantage in the United States and in

England. *JAMA* 2006; 295: 2037-2045. DOI: 10.1001/jama.295.17.2037.

53.   Mainous AG, 3rd, Diaz VA, Saxena S, et al. Diabetes management in the USA and England:

comparative analysis of national surveys. *J R Soc Med* 2006; 99: 463-469. 2006/09/02. DOI:

10.1177/014107680609900918.

54.   Desai M, Rachet B, Coleman MP, et al. Two countries divided by a common language:

health systems in the UK and USA. *J R Soc Med* 2010; 103: 283-287. 2010/07/03. DOI:

10.1258/jrsm.2010.100126.

55.   Papanicolas I, Mossialos E, Gundersen A, et al. Performance of UK National Health Service

compared with other high income countries: observational study. *BMJ* 2019; 367: l6326. DOI:

10.1136/bmj.l6326.

56.   Sallis JF, Cerin E, Conway TL, et al. Physical activity in relation to urban environments in 14

cities worldwide: a cross-sectional study. *The Lancet* 2016; 387: 2207-2217. DOI: 10.1016/S0140-

6736(15)01284-2.

57.   Prince SA, Adamo KB, Hamel ME, et al. A comparison of direct versus self-report measures

for assessing physical activity in adults: a systematic review. *Int J Behav Nutr Phys Act* 2008; 5: 56.

20081106. DOI: 10.1186/1479-5868-5-56.

58.   Dyrstad SM, Hansen BH, Holme IM, et al. Comparison of self-reported versus

accelerometer-measured physical activity. *Med Sci Sports Exerc* 2014; 46: 99-106. 2013/06/25. DOI:

10.1249/MSS.0b013e3182a0595f.

59.   Gropper H, John JM, Sudeck G, et al. The impact of life events and transitions on physical

activity: A scoping review. *PloS one* 2020; 15: e0234794.

Figure 1: Weighted distribution of systolic blood pressure, diastolic blood pressure, and cardiovascular mortality by hypertension groups in UK Biobank and NHANES

Box plots show median SBP and DBP values across normotensive, unmedicated hypertensive, and medicated hypertensive subgroups in UKBB and NAHNES, including adults aged 20 years and older. Bar plots represent cardiovascular mortality rates within each hypertension subgroup.

Figure 2: Weighted Kaplan-Meier survival curves for all-cause mortality by hypertension groups stratified by moderate-to-vigorous physical activity tertiles in UKBB and NHANES

MVPA tertiles were defined using cohort-specific distributions of accelerometer-measured daily duration of MVPA (minutes/day). For UKBB: Low (5.50–24.71), Intermediate (24.72–45.89), and High (≥45.90). For NHANES: Low (0.29–10.72), Intermediate (10.73–24.78), and High (≥24.79). Analysis included participants aged 20 years and older in UKBB and NHANES.

Comparison of United Kingdom (UK) and United States (U.S.) hypertension treatment status, physical activity and prospective mortality risk

Supplementary material

Table of contents

Supplementary Figure 1: Flow diagram of participants in the study

Supplementary Figure 2: Weighted distribution of demographic factors by hypertension groups in UK Biobank and NHANES

Box plots display median age and interquartile ranges, while bar plots show sex and ethnic group proportions across hypertension subgroups within UKBB and NHANES.

Supplementary Figure 3: Weighted distribution of hypertension groups in UK Biobank and NHANES under the 2017 American College of Cardiology/American Heart Association guideline

Bar plots depict the percentage of normotensive, unmedicated hypertensive, and medicated hypertensive participants in each cohort. Values are weighted.

Supplementary Figure 4: Hazard ratios for all-cause mortality across moderate-to-vigorous physical activity tertiles within hypertension subgroups in UK Biobank and NHANES

Each subgroup was stratified into MVPA tertiles (low, medium, high), with the low MVPA tertile serving as the reference category (HR = 1.00). HRs are presented with 95% confidence intervals. Models adjusted for age, sex, smoking status, fruit and vegetables intake, previous CVD, family history of CVD, sleep duration, educational attainment, alcohol consumption, ethnicity, and light physical activity energy expenditure.

Supplementary Figure 5: Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by moderate-to-vigorous physical activity tertiles: primary analysis and sensitivity analysis restricted to adults aged 40–69 in NHANES

The primary analysis includes all eligible NHANES participants aged ≥20 years. The sensitivity analysis is restricted to adults aged 40–69 years, to align with the age range of participants in UKBB.

Supplementary Figure 6: Weighted distribution of blood pressure and cardiovascular mortality by hypertension groups in UK Biobank and NHANES: sensitivity analysis restricted to adults aged 40–69 years in NHANES

The primary analysis includes all eligible NHANES participants aged ≥20 years. The sensitivity analysis is restricted to adults aged 40–69 years, to align with the age range of participants in UKBB.

Supplementary Figure 7: Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by moderate-to-vigorous physical activity tertiles in UK Biobank: primary analysis and sensitivity analysis excluding participants with prior cardiovascular disease

Supplementary Figure 8: Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by moderate-to-vigorous physical activity tertiles: primary and sensitivity analyses excluding participants with prior cardiovascular disease in NHANES

Supplementary Figure 9: Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by NHANES-specific moderate-to-vigorous physical activity tertiles in UK Biobank and NHANES

MVPA tertiles were defined using the NHANES distribution as follows: Low (0.29–10.72 min/day), Intermediate (10.73–24.78 min/day), and High (≥24.79 min/day). These thresholds were applied uniformly to both UKBB and NHANES.

Supplementary Figure 10: Unweighted Kaplan-Meier survival curves for all-cause mortality by hypertension groups stratified by moderate-to-vigorous physical activity tertiles in UK Biobank and NHANES

The unweighted sensitivity analysis includes all eligible participants aged ≥20 years in both cohorts and was conducted to assess whether Kaplan-Meier survival curves were influenced by weighting approaches.

Supplementary Table 1: Weighted baseline demographic, behavioural, and clinical characteristics of participants stratified by hypertension status in UK Biobank and NHANES

	Overall UKBB	Normotensive UKBB	Unmedicated HTN UKBB	Medicated HTN UKBB	Overall NHANES	Normotensive NHANES	Unmedicated HTN NHANES	Medicated HTN NHANES
n	53049	15750	31110	6190	157714415	79197815	30617498	47899102
Age, mean (s.d.), years	58.24 (8.26)	55.31 (7.42)	58.58 (8.18)	63.93 (7.29)	49.31 (16.58)	41.93 (14.71)	50.50 (15.28)	60.76 (13.26)
Female, n (%)	27888 (52.6)	10446 (66.3)	14668 (47.1)	2774 (44.8)	81057233 (51.4)	42524713 (53.7)	12576778 (41.1)	25955742 (54.2)
Ethnicity, n (%)								
White	50146 (94.5)	14800 (94.0)	29504 (94.8)	5841 (94.4)	107949339 (68.4)	52628154 (66.5)	20917441 (68.3)	34403744 (71.8)
Black	887 (1.7)	251 (1.6)	488 (1.6)	148 (2.4)	16984269 (10.8)	6604445 (8.3)	3604798 (11.8)	6775026 (14.1)
Asian	1301 (2.5)	420 (2.7)	743 (2.4)	138 (2.2)	6926901 (4.4)	4221495 (5.3)	1249162 (4.1)	1456244 (3.0)
Other	716 (1.3)	278 (1.8)	375 (1.2)	63 (1.0)	25853906 (16.4)	15743722 (19.9)	4846097 (15.8)	5264087 (11.0)
Smoking history, n (%)								

Never	30745 (58.0)	9532 (60.5)	18014 (57.9)	3200 (51.7)	80105586 (56.6)	46142249 (61.4)	15725290 (55.5)	18238046 (48.1)
Previous	17862 (33.7)	4768 (30.3)	10522 (33.8)	2572 (41.6)	35028853 (24.8)	14303349 (19.0)	7317600 (25.8)	13407905 (35.4)
Current	4442 (8.4)	1450 (9.2)	2575 (8.3)	418 (6.7)	26302250 (18.6)	14763827 (19.6)	5305744 (18.7)	6232680 (16.5)
Alcohol daily consumption, mean (s.d.)	1.93 (2.25)	1.53 (1.71)	2.08 (2.37)	2.18 (2.65)	2.57 (2.23)	2.61 (2.21)	2.64 (2.22)	2.44 (2.27)
Education, n (%)								
High school graduate, GED or equivalent	13702.4 (25.8)	4116.0 (26.1)	8068.1 (25.9)	1518.3 (24.5)	33127235.1 (21.0)	14907871.6 (18.8)	7270395.3 (23.7)	10948968.3 (22.9)
Some college or AA degree	10085.2 (19.0)	2627.2 (16.7)	6199.9 (19.9)	1258.2 (20.3)	50793895.5 (32.2)	25179272.6 (31.8)	9237213.9 (30.2)	16377409.0 (34.2)
College graduate	22327.1 (42.1)	7590.5 (48.2)	12688.6 (40.8)	2048.0 (33.1)	49859228.0 (31.6)	28494089.8 (36.0)	9656906.7 (31.5)	11708231.4 (24.5)
Other	6934.4 (13.1)	1416.2 (9.0)	4153.2 (13.4)	1365.0 (22.1)	23876102.5 (15.1)	10592293.8 (13.4)	4448313.5 (14.5)	8835495.3 (18.5)
Fruit and vegetable consumption,	7.77 (4.48)	7.83 (4.65)	7.68 (4.36)	8.07 (4.67)	4.76 (3.53)	4.84 (3.86)	4.67 (3.06)	4.68 (3.22)

mean (s.d.), servings/day								
Previous CVD, n(%)	3729.8 (7.0)	688.1 (4.4)	2123.7 (6.8)	918.0 (14.8)	14562762.3 (9.2)	2867626.7 (3.6)	1538512.5 (5.0)	10156623.1 (21.3)
Family history of CVD, n (%)	26826.5 (50.6)	7057.1 (44.8)	15907.7 (51.1)	3861.7 (62.4)	19830689.8 (12.8)	7972862.9 (10.3)	3208760.6 (10.7)	8649066.3 (18.4)
Non-exerciser, n (%)	17107.5 (32.2)	4303.3 (27.3)	10158.2 (32.7)	2645.9 (42.7)	73218637.2 (46.4)	31048363.9 (39.2)	14762375.2 (48.2)	27407898.1 (57.2)
Sleep, mean (s.d.), minutes/day	440.08 (91.78)	441.69 (96.80)	439.74 (90.59)	437.69 (84.22)	390.67 (125.14)	402.08 (119.73)	380.12 (127.52)	378.54 (130.58)
HbA1C, mean (s.d.), %	5.35 (0.51)	5.25 (0.38)	5.36 (0.52)	5.57 (0.67)	5.67 (0.98)	5.44 (0.73)	5.70 (1.04)	6.03 (1.18)
HDL, mean (s.d.), mg/dL	56.44 (14.45)	58.57 (14.36)	56.01 (14.37)	53.18 (14.29)	52.86 (15.82)	53.63 (15.14)	52.87 (18.13)	51.56 (15.27)
LDL, mean (s.d.), mg/dL	136.09 (32.18)	130.42 (30.07)	140.58 (32.09)	127.91 (33.87)	114.61 (35.50)	114.51 (33.06)	119.88 (36.35)	112.18 (38.43)
triglyceride, mean (s.d.), mg/dL	145.72 (87.33)	121.32 (70.88)	153.78 (91.03)	167.36 (92.81)	129.18 (116.30)	115.45 (128.78)	136.83 (92.45)	147.04 (102.59)
SBP, mean (s.d.), mmHg	136.02 (17.92)	117.29 (7.33)	143.28 (14.45)	147.20 (16.88)	122.23 (16.00)	112.54 (8.74)	133.80 (12.42)	130.84 (17.41)

DBP, mean (s.d.), mmHg	81.26 (10.12)	71.23 (5.06)	85.42 (8.41)	85.84 (9.68)	70.67 (10.76)	67.20 (7.87)	79.07 (10.03)	71.03 (12.23)
Waist circumference, mean (s.d.), cm	88.27 (13.09)	82.34 (11.14)	89.76 (12.65)	95.87 (13.81)	100.20 (16.11)	95.60 (14.58)	102.14 (16.01)	106.81 (16.12)
Body Mass Index, mean (s.d.), kg/m²	26.70 (4.59)	24.88 (3.69)	27.11 (4.49)	29.28 (5.35)	29.25 (6.82)	27.75 (5.92)	29.77 (6.92)	31.43 (7.49)
CVD mortality, n (%)	328.2 (0.7)	36.8 (0.2)	199.7 (0.7)	91.7 (1.7)	3634417.5 (2.3)	659032.3 (0.8)	515765.1 (1.7)	2459620.1 (5.1)
Daily MVPA duration, mean (s.d.), minutes/day	40.01 (25.23)	42.47 (25.31)	40.09 (25.24)	33.36 (23.76)	21.04 (17.37)	24.69 (17.38)	22.90 (17.28)	13.82 (15.05)

Abbreviations:

AA, Associate's degree;

GED, General Educational Development;

HDL, high-density lipoprotein cholesterol;

LDL, low-density lipoprotein cholesterol;

Supplementary Table 2: Unweighted baseline demographic, behavioural, and clinical characteristics of participants stratified by hypertension status in UK Biobank and NHANES

	Overall UKBB	Normotensive UKBB	Unmedicated HTN UKBB	Medicated HTN UKBB	Overall NHANES	Normotensive NHANES	Unmedicated HTN NHANES	Medicated HTN NHANES
n	63452	16814	37747	8891	7397	3445	1414	2538
Age, mean (s.d.), years	61.57 (7.86)	58.69 (7.80)	61.88 (7.72)	65.72 (6.33)	50.72 (17.28)	41.89 (15.26)	51.76 (15.88)	62.12 (13.31)
Female, n (%)	35790 (56.4)	11783 (70.1)	19850 (52.6)	4157 (46.8)	3749 (50.7)	1837 (53.3)	560 (39.6)	1352 (53.3)
Ethnicity, n (%)								
White	61597 (97.1)	16255 (96.7)	36741 (97.3)	8601 (96.7)	3118 (42.2)	1434 (41.6)	577 (40.8)	1107 (43.6)
Black	514 (0.8)	128 (0.8)	275 (0.7)	111 (1.2)	1719 (23.2)	584 (17.0)	360 (25.5)	775 (30.5)
Asian	675 (1.1)	203 (1.2)	374 (1.0)	98 (1.1)	796 (10.8)	472 (13.7)	144 (10.2)	180 (7.1)
Other	666 (1.0)	228 (1.4)	357 (0.9)	81 (0.9)	1764 (23.8)	955 (27.7)	333 (23.6)	476 (18.8)
Smoking history, n (%)								

Never	36444 (57.4)	10133 (60.3)	21709 (57.5)	4602 (51.8)	3685 (57.2)	1999 (61.7)	721 (56.0)	965 (50.3)
Previous	22795 (35.9)	5424 (32.3)	13563 (35.9)	3808 (42.8)	1503 (23.3)	582 (18.0)	294 (22.8)	627 (32.7)
Current	4213 (6.6)	1257 (7.5)	2475 (6.6)	481 (5.4)	1259 (19.5)	660 (20.4)	273 (21.2)	326 (17.0)
Alcohol daily consumption, mean (s.d.)	1.97 (2.17)	1.58 (1.70)	2.08 (2.25)	2.22 (2.51)	2.62 (2.33)	2.70 (2.39)	2.72 (2.29)	2.41 (2.26)
Education, n (%)								
High school graduate, GED or equivalent	15615 (24.6)	3898 (23.2)	9430 (25.0)	2287 (25.7)	1617 (21.9)	663 (19.3)	341 (24.1)	613 (24.2)
Some college or AA degree	11759 (18.5)	2877 (17.1)	7205 (19.1)	1677 (18.9)	2252 (30.5)	1067 (31.0)	411 (29.1)	774 (30.5)
College graduate	28325 (44.6)	8592 (51.1)	16429 (43.5)	3304 (37.2)	1921 (26.0)	1077 (31.3)	365 (25.8)	479 (18.9)
Other	7753 (12.2)	1447 (8.6)	4683 (12.4)	1623 (18.3)	1602 (21.7)	636 (18.5)	296 (20.9)	670 (26.4)
Fruit and vegetable consumption,	8.04 (4.35)	8.13 (4.46)	7.96 (4.29)	8.19 (4.40)	4.61 (3.36)	4.71 (3.53)	4.60 (3.24)	4.48 (3.17)

mean (s.d.), servings/day								
Previous CVD, n (%)	5199 (8.2)	903 (5.4)	2923 (7.7)	1373 (15.4)	827 (11.2)	138 (4.0)	80 (5.7)	609 (24.2)
Family history of CVD, n (%)	34776 (54.8)	8235 (49.0)	20816 (55.1)	5725 (64.4)	837 (11.6)	316 (9.4)	139 (10.1)	382 (15.4)
Non-exerciser, n (%)	20095 (31.7)	4545 (27.0)	12080 (32.0)	3470 (39.0)	3744 (50.6)	1493 (43.3)	717 (50.7)	1534 (60.4)
Sleep, mean (s.d.), minutes/day	442.38 (90.04)	444.76 (92.59)	442.10 (90.37)	439.09 (83.33)	380.91 (124.45)	394.35 (119.28)	371.41 (124.65)	367.96 (129.31)
HbA1C, mean (s.d.), %	5.38 (0.50)	5.28 (0.37)	5.37 (0.48)	5.58 (0.67)	5.80 (1.14)	5.52 (0.88)	5.82 (1.20)	6.18 (1.30)
HDL, mean (s.d.), mg/dL	57.67 (14.84)	60.09 (14.66)	57.50 (14.79)	53.87 (14.51)	52.47 (15.53)	53.05 (14.83)	52.50 (17.17)	51.65 (15.47)
LDL, mean (s.d.), mg/dL	138.08 (32.60)	133.62 (30.93)	142.46 (32.28)	127.94 (33.57)	113.20 (35.47)	114.08 (34.05)	118.57 (35.46)	109.51 (37.02)
triglyceride, mean (s.d.), mg/dL	145.93 (84.77)	122.16 (69.78)	152.11 (87.49)	164.66 (89.40)	127.58 (120.99)	117.59 (137.19)	134.05 (99.60)	138.44 (103.67)
SBP, mean (s.d.), mmHg	138.04 (18.32)	117.65 (7.25)	144.81 (14.81)	147.89 (16.93)	123.87 (16.98)	112.58 (8.75)	135.73 (12.87)	132.58 (17.80)

DBP, mean (s.d.), mmHg	81.53 (10.07)	71.20 (5.05)	85.20 (8.52)	85.45 (9.62)	70.37 (11.10)	66.84 (8.03)	78.21 (10.84)	70.78 (12.44)
Waist circumference, mean (s.d.), cm	88.11 (12.95)	82.10 (11.00)	89.16 (12.49)	95.05 (13.54)	99.70 (16.35)	94.69 (14.81)	101.23 (16.02)	105.88 (16.32)
Body mass index, mean (s.d.), kg/m²	26.63 (4.49)	24.75 (3.57)	26.93 (4.37)	28.91 (5.13)	29.20 (6.97)	27.57 (6.03)	29.57 (7.01)	31.24 (7.57)
CVD mortality, n (%)	478 (0.8)	50 (0.3)	292 (0.8)	136 (1.8)	233 (3.1)	40 (1.2)	27 (1.9)	166 (6.5)
Daily MVPA duration, mean (s.d.), minutes/day	38.41 (24.76)	41.03 (25.08)	38.70 (24.83)	32.23 (22.76)	19.75 (17.37)	24.17 (17.50)	22.13 (17.88)	12.42 (14.22)

Abbreviations:

AA, Associate's degree;

GED, General Educational Development;

HDL, high-density lipoprotein cholesterol;

LDL, low-density lipoprotein cholesterol;

Supplementary Table 3: Number of all-cause mortality events by moderate-to-vigorous physical activity tertiles within hypertension subgroups in UK Biobank and NHANES

	UKBB medicated HTN	UKBB unmedicated HTN	UKBB normotensive	NHANES medicated HTN	NHANES unmedicated HTN	NHANES normotensive
Overall	367	1,032	259	260	78	78
MVPA Tertiles						
Low	166	432	116	181	56	54
Intermediate	105	337	83	53	13	12
High	96	263	60	26	9	12
Values represent the total number of all-cause mortality events observed during follow-up in each MVPA tertile, stratified by hypertension status.						